Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer’s Disease Patients

Manuscript Number: 

16-0216R2

Author(s): 
H. Michael Arrighi, Frederik Barkhof, Jennifer Bogert, H. Robert Brashear, Jianing Di, Achim Gass, Nzeera Ketter, Yves Miaux, Derk D. Purcell

Disclosures

H. Michael Arrighi

  • Equity:
    Hold stock in Johnson and Johnson, not certain of the exact number a 1000 or so shares
    Sponsors:
    Employee of Johnson and Johnson, Jansen Pharmaceuticals Research and Development

Frederik Barkhof

  • Consulting Fees:
    Janssen, Eisai, Biogen, Riche. Consulting, Steering Committee and DSMB

Jennifer Bogert

  • Equity:
    own Johnson & Johnson stock options
    Sponsors:
    statistician

H. Robert Brashear

  • Equity:
    I am an employee of and receive stock from Janssen Research and Development, LLC
    Sponsors:
    I am an employee of and receive stock from Janssen Research and Development, LLC.

Jianing Di

  • Equity:
    regular long term incentives offered to J&J employees

Achim Gass

  • Nothing to Disclose

Nzeera Ketter

  • Equity:
    Johnson and Johnson
    Sponsors:
    Johnson and Johnson (Janssen) Neuroscience

Yves Miaux

  • Lecture Fees:
    Dr. Miaux executed and interpreted central final read of brain MRI scans

Derk D. Purcell

  • Consulting Fees:
    Central reader for imaging CRO (Bioclinica)